JOP20170044B1 - تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو - Google Patents
تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النموInfo
- Publication number
- JOP20170044B1 JOP20170044B1 JOP/2017/0044A JOP20170044A JOP20170044B1 JO P20170044 B1 JOP20170044 B1 JO P20170044B1 JO P20170044 A JOP20170044 A JO P20170044A JO P20170044 B1 JOP20170044 B1 JO P20170044B1
- Authority
- JO
- Jordan
- Prior art keywords
- growth hormone
- hormone deficiency
- patient
- pharmaceutical composition
- dosage
- Prior art date
Links
- 206010056438 Growth hormone deficiency Diseases 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010033310 GX-H9 Proteins 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
يتعلق الكشف الحالي بطريقة إعطاء هرمون نمو بشري ناتج عن إعادة الارتباط الجيني GX-H9 لعلاج نقص هرمون النمو. وبالتحديد، يتعلق الكشف الحالي بتركيبة صيدلانية لعلاج نقص هرمون النمو، تتضمن هرمون النمو البشري hGH GX-H9 ناتج عن إعادة الارتباط الجيني ومادة حاملة مقبولة صيدلانيا، وفيها يتم إعطاء GX-H9 الناتج عن إعادة الارتباط الجيني مرة واحدة أسبوعيا بجرعة تتراوح من 0.1 الى 0.3 مجم لكل كجم من وزن مريض أو مرتين شهريا بجرعة تتراوح من 0.1 الى 0.4 مجم لكل كجم من وزن مريض. علاوة على ذلك، يتعلق الاختراع الحالي بطريقة علاج نقص هرمون النمو تتضمن إعطاء هرمون النمو البشريandnbsp; hGH GX-H9 الناتج عن إعادة الارتباط الجيني لمريض يعاني من نقص هرمون النمو مرة واحدة أسبوعيا بجرعة تتراوح من 0.1 الى 0.3 مجم لكل كجم من وزن المريض أو مرتين شهريا بجرعة تتراوح من 0.1 الى 0.4 مجم لكل كجم من وزن المريض
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160018695 | 2016-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20170044B1 true JOP20170044B1 (ar) | 2021-08-17 |
Family
ID=59761652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0044A JOP20170044B1 (ar) | 2016-02-17 | 2017-02-16 | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210177945A1 (ar) |
EP (1) | EP3416677B1 (ar) |
JP (1) | JP6896749B2 (ar) |
KR (2) | KR20170096968A (ar) |
CN (1) | CN109152816B (ar) |
BR (1) | BR112018016817A2 (ar) |
CA (1) | CA3014164A1 (ar) |
DK (1) | DK3416677T3 (ar) |
ES (1) | ES2925901T3 (ar) |
HU (1) | HUE059593T2 (ar) |
JO (1) | JOP20170044B1 (ar) |
PL (1) | PL3416677T3 (ar) |
PT (1) | PT3416677T (ar) |
RU (1) | RU2732113C2 (ar) |
TW (1) | TWI748990B (ar) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
CA3238895A1 (en) | 2021-11-26 | 2023-06-01 | Genexine, Inc. | High-concentration administration formulation of hgh fusion protein |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2426485T3 (es) * | 2006-08-31 | 2013-10-23 | Novartis Ag | Composiciones farmacéuticas que comprenden hGH para administración oral |
KR101380729B1 (ko) * | 2007-05-30 | 2014-04-10 | 포항공과대학교 산학협력단 | 면역글로불린 융합 단백질 |
CN102875683B (zh) * | 2011-07-11 | 2014-06-11 | 旭华(上海)生物研发中心有限公司 | 长效重组人生长激素的Fc融合蛋白 |
DK2858664T3 (da) * | 2012-06-05 | 2019-07-08 | Amunix Pharmaceuticals Inc | Hgh-xten-fusionsprotein og anvendelse deraf i behandling af væksthormonmangel |
JP2016514132A (ja) * | 2013-03-11 | 2016-05-19 | アムニクス オペレーティング インコーポレイテッド | ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療 |
US20160015789A1 (en) * | 2014-07-17 | 2016-01-21 | Teva Pharmaceutical Industries, Ltd. | FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN |
WO2018044060A1 (en) * | 2016-08-30 | 2018-03-08 | Genexine,Inc. | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN |
-
2017
- 2017-02-16 BR BR112018016817A patent/BR112018016817A2/pt unknown
- 2017-02-16 DK DK17753492.2T patent/DK3416677T3/da active
- 2017-02-16 CN CN201780018326.9A patent/CN109152816B/zh active Active
- 2017-02-16 PL PL17753492.2T patent/PL3416677T3/pl unknown
- 2017-02-16 PT PT177534922T patent/PT3416677T/pt unknown
- 2017-02-16 KR KR1020170021104A patent/KR20170096968A/ko not_active Application Discontinuation
- 2017-02-16 JP JP2018543675A patent/JP6896749B2/ja active Active
- 2017-02-16 CA CA3014164A patent/CA3014164A1/en active Pending
- 2017-02-16 RU RU2018132694A patent/RU2732113C2/ru active
- 2017-02-16 HU HUE17753492A patent/HUE059593T2/hu unknown
- 2017-02-16 JO JOP/2017/0044A patent/JOP20170044B1/ar active
- 2017-02-16 US US16/077,177 patent/US20210177945A1/en active Pending
- 2017-02-16 ES ES17753492T patent/ES2925901T3/es active Active
- 2017-02-16 EP EP17753492.2A patent/EP3416677B1/en active Active
- 2017-02-17 TW TW106105296A patent/TWI748990B/zh active
-
2018
- 2018-12-13 KR KR1020180161061A patent/KR102312986B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20180135839A (ko) | 2018-12-21 |
KR20170096968A (ko) | 2017-08-25 |
RU2732113C2 (ru) | 2020-09-11 |
US20210177945A1 (en) | 2021-06-17 |
EP3416677A4 (en) | 2019-11-06 |
PL3416677T3 (pl) | 2022-11-21 |
EP3416677A1 (en) | 2018-12-26 |
RU2018132694A3 (ar) | 2020-03-17 |
RU2018132694A (ru) | 2020-03-17 |
BR112018016817A2 (pt) | 2018-12-26 |
JP6896749B2 (ja) | 2021-06-30 |
CN109152816B (zh) | 2022-08-16 |
TW201729831A (zh) | 2017-09-01 |
DK3416677T3 (da) | 2022-08-29 |
JP2019508421A (ja) | 2019-03-28 |
PT3416677T (pt) | 2022-09-06 |
CA3014164A1 (en) | 2017-08-24 |
KR102312986B1 (ko) | 2021-10-14 |
TWI748990B (zh) | 2021-12-11 |
CN109152816A (zh) | 2019-01-04 |
ES2925901T3 (es) | 2022-10-20 |
EP3416677B1 (en) | 2022-08-03 |
HUE059593T2 (hu) | 2022-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012884A (es) | Terapia de combinacion. | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
RU2014102924A (ru) | Композиция для контролируемой стимуляции яичников | |
MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
PH12018550210A1 (en) | Oral dosage form with drug composition, barrier layer and drug layer | |
NZ617397A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
NZ751972A (en) | Treatment of prurigo nodularis | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
JP2018522881A5 (ar) | ||
MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
NZ760033A (en) | Methods to treat opioid use disorder |